Shane Kovacs, Executive VP & CFO of PTC Therapeutics, Inc., provided testimony on behalf of BIO before the U.S. House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises, addressing legislative proposals to enhance capital formation and reduce regulatory burdens. Current bills being considered could help to further support the search for breakthrough treatments at emerging growth biotech companies.